Table 2.
Unsuccessful or terminated phase III trials with anti-VEGF pathway agents
| Combined with | Tumor (setting) | ↑ PFS? | ↑ OS? | Identifier |
|---|---|---|---|---|
| Bevacizumab | ||||
| XELOX and cetuximab | CRC (1st) | No*‡ | NA | PACCE115 |
| Oxaliplatin or irinotecan and panitumumab | CRC (1st) | No*‡ | NA | CAIRO2116 |
| FOLFOX | CRC (adjuvant) | No§ | NA | NSABP-C-0889 |
| Capecitabine | MBC (2nd) | No* | No | AVF2119117 |
| Erlotinib | NSCLC (2nd) | Yes | No* | BeTa118 |
| Capecitabine or 5-FU and cisplatin | AGC (1st) | Yes | No* | AVAGAST119 |
| Gemcitabine | PC (1st) | No | No* | CALGB80303120 |
| Gemcitabine and erlotinib | PC (1st) | Yes | No* | AviTA121 |
| Docetaxol and prednisone | PC (1st) | Yes | No* | CALGB90401122 |
| FOLFOX or XELOX | CRC (adjuvant) | No§ | NA | AVANT24 |
| Aflibercept | ||||
| Gemcitabine | PC (1st) | NA | No* | VANILLA‖ |
| Sunitinib | ||||
| Paclitaxol | MBC (1st) | No* | NA | SUN 1094‖ |
| Capcitabine | MBC (2nd) | No* | No | SUN 1099123 |
| Docetaxol | MBC (1st) | No* | No | SUN 1064‖ |
| FOLFIRI | CRC (1st) | No* | NA | SUN 1122‖ |
| Erlotinib | NSCLC (2nd) | Yes | No* | SUN 1087‖ |
| Monotherapy | MBC (2nd) | No* | No | SUN 1107124 |
| Monotherapy | HCC (2nd) | NA | No | SUN 1107‖ |
| Hormone therapy and prednisone | PR (2nd) | NA | No* | SUN 1120‖ |
| Sorafenib | ||||
| Carboplatin and paclitaxol | MM (2nd) | No | No* | PRISM‖ |
| Carboplatin and paclitaxol | NSCLC (1st) | No | No* | ESCAPE125 |
| PTK787 | ||||
| FOLFOX | CRC (2nd) | Yes | No* | CONFIRM 2126 |
| FOLFOX | CRC (1st) | No | No* | CONFIRM 1‖ |
| Semaxanib | ||||
| FOLFIRI | CRC (1st) | NA | No* | NCT00021281‖ |
| Leucovorin and 5-FU | CRC (1st) | NA | No* | NCT00004252‖ |
| Axitinib | ||||
| Gemcitabine | PC (1st) | NA | No* | A4061028‖ |
| Vandetanib | ||||
| Monotherapy | NSCLC (2nd) | No* | No | ZEST127 |
| Pemetrexed | NSCLC (2nd) | No* | No | ZEAL128 |
| Cediranib | ||||
| FOLFOX | CRC (1st) | Yes | No* | HORIZON III‖ |
| Monotherapy or lomustine | GBM (2nd) | No* | No | REGAL129 |
*
Primary end point.
‡
PFS worse in experimental arm.
§
Disease-free survival.
‖
No citation available, study terminated.
Abbreviations: ↑, increased; 5-FU, 5-fluorouracil; AGC, advanced gastric cancer; CRC, colorectal cancer; FOLFIRI, 5-FU, leucovorin and irinotecan; FOLFOX, 5-FU, leucovorin and oxaliplatin; GBM, glioblastoma multiforme; HCC, hepatocellular carcinoma; MBC, metastatic breast cancer; MM, metastatic melanoma; NA, not available (pending, unknown or not reported); NSCLC, non-small-cell lung cancer; OS, overall survival; PC, pancreatic cancer; PFS, progression-free survival; PR, prostate cancer; XELOX, capecitabine and oxaliplatin.